GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » Price-to-Tangible-Book

Sage Therapeutics (Sage Therapeutics) Price-to-Tangible-Book : 1.21 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Price-to-Tangible-Book?

As of today (2024-04-29), Sage Therapeutics's share price is $14.24. Sage Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $11.73. Hence, Sage Therapeutics's Price to Tangible Book Ratio of today is 1.21.

The historical rank and industry rank for Sage Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

SAGE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17   Med: 4.14   Max: 14.55
Current: 1.21

During the past 12 years, Sage Therapeutics's highest Price to Tangible Book Ratio was 14.55. The lowest was 1.17. And the median was 4.14.

SAGE's Price-to-Tangible-Book is ranked better than
79.18% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs SAGE: 1.21

A closely related ratio is called PB Ratio. As of today, Sage Therapeutics's share price is $14.24. Sage Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $11.73. Hence, Sage Therapeutics's P/B Ratio of today is 1.21.


Sage Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Sage Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Price-to-Tangible-Book Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.96 2.43 1.45 1.81 1.63

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.21 2.86 1.51 1.63 1.60

Competitive Comparison of Sage Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Sage Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Price-to-Tangible-Book falls into.



Sage Therapeutics Price-to-Tangible-Book Calculation

Sage Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=14.24/11.728
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Sage Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (Sage Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Executives
Elizabeth Barrett director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas director, officer: See Remarks ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault officer: Chief Medical Officer C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi officer: Chief Commercial Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates director 88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud officer: Chief Scientific Officer 215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan officer: Chief Business Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook officer: General Counsel 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi officer: See Remarks 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035

Sage Therapeutics (Sage Therapeutics) Headlines

From GuruFocus

Sage Therapeutics to Present at Upcoming May Investor Conferences

By Business Wire Business Wire 05-03-2023